Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LORTAB vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Moderate to severe pain management (FDA),Off-label: acute pain, chronic pain
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Hydrocodone: CYP3A4, CYP2D6; acetaminophen: hepatic conjugation (glucuronidation, sulfation) and CYP450 (minor).
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Hydrocodone: ~20-30% bound (primarily albumin).
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Hydrocodone: 3.3-4.7 L/kg; indicates extensive tissue distribution.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral: ~90% (first-pass metabolism reduces to ~50% due to extensive hepatic extraction; absolute bioavailability not well defined, but high oral absorption).
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Hydrocodone: e GFR 30-59 m L/min: administer 50-75% of usual dose; e GFR 15-29 m L/min: 50% of usual dose; e GFR <15 m L/min: avoid or use with caution. Acetaminophen: no specific GFR-based adjustment; avoid in severe renal impairment due to metabolite accumulation.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Hydrocodone: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: avoid. Acetaminophen: reduce dose or avoid in significant liver disease; maximum 2000 mg/day in mild-moderate impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not recommended for children <18 years due to risk of respiratory depression and acetaminophen toxicity. In specific circumstances, weight-based dosing for hydrocodone 0.1-0.2 mg/kg/dose every 4-6 hours, max 10 mg/dose; acetaminophen 10-15 mg/kg/dose, max 60 mg/kg/day, not to exceed 3000 mg/day.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Start at the low end of dosing range (e.g., 1 tablet of 5 mg hydrocodone/325 mg acetaminophen every 6 hours). Monitor for respiratory depression, sedation, and constipation. Avoid acetaminophen >3000 mg/day due to hepatotoxicity risk.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with CYP3A4 inhibitors or discontinuation; risk of medication errors.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Addiction, abuse, misuse; respiratory depression; head injury; GI obstruction; hepatic toxicity; renal impairment; hypotension; adrenal insufficiency; seizures; serotonin syndrome; severe hypotension; risk with MAOIs; pregnancy; lactation.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity; respiratory depression; acute/severe asthma; GI obstruction; suspected surgical abdomen; severe hepatic impairment; concurrent use with MAOIs or within 14 days.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Avoid grapefruit and grapefruit juice as they may alter hydrocodone metabolism. Alcohol must be strictly avoided due to additive CNS depression and increased acetaminophen hepatotoxicity. No other significant food interactions.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
FDA Category C in 1st and 2nd trimesters; increased risk of neural tube defects and congenital heart defects with codeine use; risk of respiratory depression and neonatal withdrawal syndrome in 3rd trimester with prolonged use.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Codeine is excreted into breast milk; M/P ratio approximately 2.5 for morphine (active metabolite); potential for infant CNS depression; use caution, especially in CYP2D6 ultra-rapid metabolizers.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Increased clearance of codeine in pregnancy may require higher doses or more frequent intervals; avoid in 3rd trimester due to risk of neonatal respiratory depression; use lowest effective dose for shortest duration.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Lortab (hydrocodone/acetaminophen) carries a boxed warning for respiratory depression, misuse/abuse, and neonatal opioid withdrawal syndrome. The acetaminophen component imposes a maximum dose of 4000 mg/day; caution with hepatic impairment. Use the lowest effective dose for the shortest duration. Consider naloxone co-prescribing for high-risk patients.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve tablets; swallow whole.,Avoid alcohol; it increases risk of liver damage and respiratory depression.,Do not drive or operate machinery until you know how Lortab affects you.,Discontinue and seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or liver injury (yellowing skin/eyes, dark urine).,Store securely out of reach of others; dispose of unused medication via take-back programs.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LORTAB vs ANEXSIA 7.5/650, answered by our medical review team.
LORTAB is a Opioid analgesic combination that works by Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LORTAB and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LORTAB is: 1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LORTAB and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LORTAB is classified as Category C. FDA Category C in 1st and 2nd trimesters; increased risk of neural tube defects and congenital heart defects with codeine use; risk of respiratory depression and neonatal withdrawa. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.